Guillain-Barré syndrome after mRNA-1273 (Moderna) COVID-19 vaccination: A case report

Authors

Zauraiz Anjum, Rochester Regional HealthFollow
Charoo Iyer, Rochester Regional HealthFollow
Maryrose Laguio-Vila, Rochester Regional HealthFollow
Sanjay Anandaram, Rochester Regional HealthFollow

Department

Medicine

Document Type

Article

Publication Title

Clinical Case Reports

Abstract

Guillain-Barre syndrome (GBS) is an acquired inflammatory polyradiculoneuropathy that often follows infection with a virus or bacteria and in rare occasions, vaccination may precede GBS. We present a case of 80-year-old male patient who presented with chief complaints of progressive, ascending bilateral lower extremity paresthesia and weakness following first dose of Moderna vaccine. His symptoms got exacerbated after 2nd dose. Clinical examination and investigation findings including lumbar puncture, nerve conduction study, and electromyography were consistent with the diagnosis of GBS. The patient received treatment with intravenous immunoglobulin and there was significant improvement toward the end of 5th day. Though rare, this case report suggest that physician should remain vigilant for GBS following COVID-19 vaccination.

First Page

e05733

DOI

10.1002/ccr3.5733

Volume

10

Issue

4

Publication Date

4-14-2022

Comments

See full list of authors at journal website.

PubMed ID

35441015

Recommended Citation

Anjum, Z., Iyer, C., Laguio-Vila, M., & Anandaram, S. (2022). Guillain-Barré syndrome after mRNA-1273 (Moderna) COVID-19 vaccination: A case report. Clinical Case Reports, 10 (4), e05733. https://doi.org/10.1002/ccr3.5733